Status:
UNKNOWN
Pre-eclampsia and Metabolomics
Lead Sponsor:
Université de Sherbrooke
Collaborating Sponsors:
Foundation of the Stars
Conditions:
Preeclampsia
Eligibility:
FEMALE
18-40 years
Brief Summary
The hypertensive disorders of pregnancy are the medical complications more prevalent during pregnancy. In Canada, approximately 1% of pregnancies have complications due to a pre-existing hypertension,...
Detailed Description
Metabolomics involves a new technology using the methods of separation and detection complex to investigate a set of small molecules that characterize biochemical pathways of interest. The change in c...
Eligibility Criteria
Inclusion
- Case group: Women hospitalized for pre-eclampsia after 20 0/7 weeks of gestation. The diagnosis of preeclampsia include a combination of the following criteria: after 20 weeks of pregnancy in a previously normotensive woman, a diastolic blood pressure ≥ 90 mmHg recorded twice at least four hours apart or ≥ 110 mmHg, with proteinuria ≥ 300 mg/24h or ≥ 30 mg / mmol protein / urinary creatinine in a urine sample or factor (s) serious maternal / fetal (according to consensus SOGC).
- Control group: Women will be matched to women with preeclampsia according to gestational age at diagnosis of pre-eclampsia, maternal age (in stratum of 5 years), gender, ethnicity (4 categories: Caucasian, black, Asian and other) and body mass index (5 classes: \< 20, 20-25, 26-30, 31-35 and \< 35). Patients of this group should be at low risk of obstetric complications at recruitment and planning to deliver at the CHUS.
Exclusion
- \- Minor patients, patients with post-partum preeclampsia, premature rupture of membranes, a severe congenital fetal malformation, twin pregnancies and fetal death. Patients with underlying diseases taht could be associated with preeclampsia as pre-existing hypertension (ie before 20SA), anti-phospholipid syndrome, lupus, type DM 1-2, nephropathy, etc will be excluded. Patients who have a complication during the pregnancy will be excluded from the control group.
Key Trial Info
Start Date :
March 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2017
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00939575
Start Date
March 1 2009
End Date
March 1 2017
Last Update
March 4 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre hospitalier de l'Université de Sherbrooke
Sherbrooke, Quebec, Canada, J1H 5N4